Rhumbline Advisers Solid Biosciences Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q4 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.43 - $1.24 $30,810 - $88,848	-71,652 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$0.74 - $1.79 $5,367 - $12,982	-7,253 Reduced 9.19%	71,652 $86,000
Q4 2021 Feb 10, 2022	BUY	$1.69 - $2.46 $7,267 - $10,578	4,300 Added 5.76%	78,905 $138,000
Q3 2021 Nov 12, 2021	BUY	$2.38 - $3.77 $3,988 - $6,318	1,676 Added 2.3%	74,605 $178,000
Q2 2021 Aug 05, 2021	BUY	$3.49 - $5.51 $132,176 - $208,680	37,873 Added 108.04%	72,929 $267,000
Q1 2021 May 06, 2021	BUY	$5.37 - $10.72 $295 - $589	55 Added 0.16%	35,056 $194,000
Q4 2020 Feb 10, 2021	BUY	$3.08 - $7.79 $20,515 - $51,889	6,661 Added 23.5%	35,001 $265,000
Q3 2020 Nov 12, 2020	SELL	$2.02 - $3.08 $14,228 - $21,695	-7,044 Reduced 19.91%	28,340 $58,000
Q2 2020 Aug 13, 2020	BUY	$2.1 - $3.42 $18,343 - $29,873	8,735 Added 32.78%	35,384 $104,000
Q1 2020 May 06, 2020	BUY	$2.31 - $4.43 $1,732 - $3,322	750 Added 2.9%	26,649 $64,000
Q4 2019 Feb 05, 2020	BUY	$2.82 - $12.9 $5,800 - $26,535	2,057 Added 8.63%	25,899 $115,000
Q3 2019 Oct 23, 2019	BUY	$4.33 - $11.64 $17,727 - $47,654	4,094 Added 20.73%	23,842 $247,000
Q2 2019 Aug 14, 2019	BUY	$4.6 - $10.13 $20,930 - $46,091	4,550 Added 29.94%	19,748 $114,000
Q1 2019 May 01, 2019	SELL	$7.19 - $32.37 $3,206 - $14,437	-446 Reduced 2.85%	15,198 $140,000
Q4 2018 Jan 31, 2019	BUY	$21.32 - $46.34 $122,057 - $265,296	5,725 Added 57.72%	15,644 $419,000
Q3 2018 Nov 07, 2018	BUY	$36.35 - $51.7 $48,527 - $69,019	1,335 Added 15.55%	9,919 $468,000
Q2 2018 Aug 06, 2018	BUY	$7.33 - $43.15 $62,920 - $370,399	8,584 New	8,584 $306,000

Others Institutions Holding SLDB

# of Institutions

Shares Held

Call Options Held

Put Options Held

View Full List

About Solid Biosciences Inc.

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $25.1M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

More about SLDB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account